as mania in bipolar disorder, and for treatment of psychosis in Parkinson's Disease, wherein Compound (I) is administered semiweekly, weekly or biweekly in a dose corresponding to between 20 mg/week and 50 mg/week.calculated as the free base of Compound (I).

8. Compound (I) according to claim 1 or the use of Compound (I) according to claim 7 and or and a further compound selected from the group consisting of sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant for the preparation of a medicament for the treatment of psychosis, in particular schizophrenia or other diseases involving psychotic symptoms, such as, e.g., Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder as well other psychotic disorders or diseases that present with psychotic symptoms, e.g. bipolar disorder, such as mania in bipolar disorder, and for treatment of psychosis in Parkinson's Disease, wherein Compound (I) is administered semiweekly, weekly or biweekly in a dose corresponding to between 20 mg/week and 50 mg/week.calculated as the free base of Compound (I).

~~9. A method of treating a patient suffering from a psychosis, in particular schizophrenia or other diseases involving psychotic symptoms, such as, e.g., Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder as well other psychotic disorders or diseases that present with psychotic symptoms, e.g. bipolar disorder, such as mania in bipolar disorder, and for treatment of psychosis in Parkinson's Disease; which method comprises administering an effective amount of Compound (I) to a patient, alone or in combination with one or more neuroleptic agents selected from sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant, wherein Compound (I) is administered semiweekly, weekly or biweekly in a dose corresponding to between 20 mg/week and 50 mg/week.calculated as the free base of Compound (I).~~

~~10.~~9. A pharmaceutical composition comprising Compound (I) or a salt of Compound (I) and one or more pharmaceutically acceptable carriers, diluents and excipients for the treatment of a disease in the central nervous system, in particular psychosis, such as schizophrenia, characterized in that the pharmaceutical composition comprising Compound (I) is administered semiweekly, weekly or biweekly.

~~11.~~10. The pharmaceutical composition of claim ~~10~~9 further comprising one or more neuroleptic agents selected from sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.